AIM
VYGR icon

Acrospire Investment Management’s Voyager Therapeutics VYGR Stock Holding History

Acrospire Investment Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,106
Closed -$45K – 2169
2016
Q2 		$45K Buy
+4,106
New +$50.2K 0.03% 1142

Other funds holding VYGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acrospire Investment Management's VYGR Position: Q3 2016 in Review

Acrospire Investment Management sold out of Voyager Therapeutics (VYGR) in Q3 2016, closing a stake of 4,106 shares — an estimated $45K sold.

Acrospire Investment Management first reported a position in VYGR in Q2 2016 and held it in 1 quarter. The position peaked at $45K in Q2 2016. 52 funds tracked by Wall St. Rank hold VYGR as of Q3 2016.

  • Acrospire Investment Management reported no remaining Voyager Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 4,106 Voyager Therapeutics shares in Q3 2016, an estimated $45K.
  • Acrospire Investment Management first reported a position in Voyager Therapeutics in Q2 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Voyager Therapeutics position peaked at $45K in Q2 2016.
  • 52 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2016.

Based on Acrospire Investment Management's 13F filing for Q3 2016, filed 10 Nov 2016.